Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 125

Results For "CRO"

4169 News Found

Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC
News | November 05, 2024

Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies


Biocon reports Q2 FY25 net loss at Rs. 16 Cr
News | November 04, 2024

Biocon reports Q2 FY25 net loss at Rs. 16 Cr

Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore


USFDA inspection of Shilpa Medicare Unit VI at Bengaluru
Drug Approval | November 02, 2024

USFDA inspection of Shilpa Medicare Unit VI at Bengaluru

The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature


Supriya Lifescience reports 19% revenue increase in Q2 FY25
News | November 01, 2024

Supriya Lifescience reports 19% revenue increase in Q2 FY25

The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24


AbbVie to acquire Aliada Therapeutics
News | November 01, 2024

AbbVie to acquire Aliada Therapeutics

Strengthening focus in Alzheimer's disease and neuroscience pipeline


Prime Minister launches expansion of health coverage for citizens of and above 70 years
News | October 30, 2024

Prime Minister launches expansion of health coverage for citizens of and above 70 years

Union Government will provide a health cover of Rs. 5 lakh to any elderly person above 70 years of age


Strides Pharma Science reports Q2 FY25 consolidated PAT at Rs. 93.23 Cr
News | October 28, 2024

Strides Pharma Science reports Q2 FY25 consolidated PAT at Rs. 93.23 Cr

Strides Pharma Science has reported total income of Rs. 1,229.52 crores during the period ended September 30, 2024


Indoco Remedies posts Q2 FY25 consolidated loss at Rs. 9.57 Cr
News | October 28, 2024

Indoco Remedies posts Q2 FY25 consolidated loss at Rs. 9.57 Cr

Indoco Remedies has reported total income of Rs. 434.22 crores during the period ended September 30, 2024


Laurus Labs posts Q2 FY25 consolidated PAT at Rs. 19.84 Cr
News | October 28, 2024

Laurus Labs posts Q2 FY25 consolidated PAT at Rs. 19.84 Cr

Laurus Labs has reported total income of Rs. 1,228.30 crores during the period ended September 30, 2024